MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock from...
$66,423K
Proceeds from issuance of
common stock through...
$108K
Proceeds from issuance of
common stock through...
$19K
Net cash provided by
financing activities
$66,011K
Canceled cashflow
$539K
Net change in cash,
cash equivalents and...
-$1,028K
Canceled cashflow
$66,011K
Prepaid expenses and
other assets
-$7,334K
Stock-based compensation
$4,997K
Amortization of right-of-use
assets
$889K
Other receivables
-$863K
Depreciation and
amortization
$664K
Maturities of
available-for-sale investment...
$88,457K
Proceeds from sale of
property and equipment
$12K
Principal paid on finance
lease liabilities
$539K
Net cash used in
operating activities
-$61,986K
Canceled cashflow
$14,747K
Net cash (used in)
provided by investing...
-$5,053K
Canceled cashflow
$88,469K
Consolidated net loss
-$74,123K
Accretion of discount of
available-for-sale investment...
$1,854K
Operating lease liability
-$711K
Accounts payable and
accrued expenses
-$33K
Gain on disposal of
property and equipment
$12K
Purchases of
available-for-sale investment...
$93,445K
Purchases of property and
equipment
$77K
Back
Back
Cash Flow
source: myfinsight.com
aTYR PHARMA INC (ATYR)
aTYR PHARMA INC (ATYR)